 Ronina Covar
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 77 | 2023 | 2225 | 5.670 |
Why?
| | Anti-Asthmatic Agents | 29 | 2021 | 374 | 3.110 |
Why?
| | Bronchial Provocation Tests | 6 | 2022 | 51 | 1.630 |
Why?
| | Bronchodilator Agents | 15 | 2019 | 245 | 1.530 |
Why?
| | Adrenal Cortex Hormones | 15 | 2022 | 532 | 1.470 |
Why?
| | Respiratory Sounds | 12 | 2022 | 118 | 1.270 |
Why?
| | Budesonide | 9 | 2016 | 89 | 1.140 |
Why?
| | Bronchial Hyperreactivity | 5 | 2018 | 109 | 1.070 |
Why?
| | Eosinophilia | 2 | 2023 | 204 | 0.850 |
Why?
| | Nedocromil | 5 | 2016 | 32 | 0.820 |
Why?
| | Albuterol | 10 | 2018 | 105 | 0.810 |
Why?
| | Administration, Inhalation | 22 | 2022 | 673 | 0.800 |
Why?
| | Glucocorticoids | 11 | 2019 | 582 | 0.800 |
Why?
| | Androstadienes | 7 | 2016 | 106 | 0.790 |
Why?
| | Fluticasone | 10 | 2019 | 90 | 0.780 |
Why?
| | Respiratory Function Tests | 13 | 2018 | 581 | 0.770 |
Why?
| | Lung | 8 | 2022 | 3940 | 0.770 |
Why?
| | Forced Expiratory Volume | 16 | 2022 | 508 | 0.670 |
Why?
| | Respiratory Mechanics | 1 | 2020 | 65 | 0.640 |
Why?
| | Anti-Inflammatory Agents | 10 | 2016 | 482 | 0.630 |
Why?
| | Leukotriene Antagonists | 6 | 2016 | 43 | 0.610 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 6 | 0.580 |
Why?
| | Nitric Oxide | 6 | 2023 | 896 | 0.550 |
Why?
| | Child | 49 | 2023 | 20962 | 0.510 |
Why?
| | Acetates | 7 | 2014 | 100 | 0.480 |
Why?
| | Double-Blind Method | 19 | 2021 | 1877 | 0.480 |
Why?
| | Quinolines | 7 | 2014 | 156 | 0.460 |
Why?
| | Marijuana Smoking | 1 | 2018 | 247 | 0.450 |
Why?
| | Eosinophils | 6 | 2023 | 324 | 0.440 |
Why?
| | Precision Medicine | 4 | 2021 | 385 | 0.420 |
Why?
| | Child, Preschool | 35 | 2022 | 10522 | 0.420 |
Why?
| | Humans | 85 | 2023 | 129847 | 0.410 |
Why?
| | Sputum | 4 | 2023 | 302 | 0.400 |
Why?
| | Adrenergic beta-Agonists | 4 | 2013 | 133 | 0.390 |
Why?
| | Cannabis | 1 | 2018 | 462 | 0.350 |
Why?
| | Phenotype | 4 | 2020 | 3062 | 0.340 |
Why?
| | Biomarkers | 10 | 2023 | 3971 | 0.340 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 36 | 0.340 |
Why?
| | Docosahexaenoic Acids | 1 | 2010 | 82 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1368 | 0.320 |
Why?
| | Salmeterol Xinafoate | 6 | 2019 | 41 | 0.320 |
Why?
| | Adolescent | 31 | 2022 | 20451 | 0.320 |
Why?
| | Male | 53 | 2020 | 63759 | 0.300 |
Why?
| | Ibuprofen | 2 | 2021 | 81 | 0.300 |
Why?
| | Spirometry | 9 | 2022 | 257 | 0.270 |
Why?
| | Female | 52 | 2020 | 68829 | 0.270 |
Why?
| | Drug Therapy, Combination | 7 | 2016 | 1042 | 0.270 |
Why?
| | Antioxidants | 1 | 2010 | 558 | 0.260 |
Why?
| | Breath Tests | 3 | 2023 | 87 | 0.260 |
Why?
| | Treatment Outcome | 15 | 2019 | 10241 | 0.250 |
Why?
| | Disease Progression | 9 | 2018 | 2628 | 0.250 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 78 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 1000 | 0.220 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 198 | 0.210 |
Why?
| | Microbiota | 2 | 2023 | 734 | 0.210 |
Why?
| | Severity of Illness Index | 12 | 2021 | 2739 | 0.210 |
Why?
| | Beclomethasone | 2 | 2015 | 27 | 0.210 |
Why?
| | Ribonucleases | 1 | 2003 | 54 | 0.210 |
Why?
| | Mycobiome | 1 | 2023 | 9 | 0.210 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2005 | 321 | 0.200 |
Why?
| | Larynx | 1 | 2023 | 60 | 0.200 |
Why?
| | Prospective Studies | 8 | 2023 | 7158 | 0.200 |
Why?
| | Respiration | 1 | 2003 | 193 | 0.190 |
Why?
| | Antigens, Dermatophagoides | 1 | 2022 | 10 | 0.190 |
Why?
| | Muscarinic Antagonists | 1 | 2022 | 27 | 0.190 |
Why?
| | Dietary Supplements | 2 | 2020 | 532 | 0.190 |
Why?
| | Airway Obstruction | 2 | 2022 | 154 | 0.190 |
Why?
| | Azithromycin | 2 | 2015 | 93 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 340 | 0.190 |
Why?
| | Prednisone | 4 | 2016 | 234 | 0.180 |
Why?
| | Models, Biological | 1 | 2008 | 1724 | 0.180 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 177 | 0.170 |
Why?
| | Infant | 15 | 2022 | 9018 | 0.170 |
Why?
| | Cholecalciferol | 1 | 2020 | 56 | 0.170 |
Why?
| | Leukocyte Count | 4 | 2019 | 326 | 0.160 |
Why?
| | Methacholine Chloride | 3 | 2022 | 52 | 0.160 |
Why?
| | Cross-Over Studies | 6 | 2019 | 521 | 0.160 |
Why?
| | Mometasone Furoate | 1 | 2019 | 5 | 0.160 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 36 | 0.160 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 19 | 0.160 |
Why?
| | Vitamins | 1 | 2020 | 173 | 0.160 |
Why?
| | Symbiosis | 1 | 2019 | 71 | 0.160 |
Why?
| | Minority Groups | 1 | 2021 | 250 | 0.150 |
Why?
| | Social Class | 1 | 2021 | 259 | 0.150 |
Why?
| | Risk Factors | 8 | 2016 | 9801 | 0.150 |
Why?
| | Population | 1 | 2018 | 34 | 0.150 |
Why?
| | Cyclopropanes | 7 | 2014 | 89 | 0.140 |
Why?
| | Acetaminophen | 2 | 2021 | 248 | 0.140 |
Why?
| | Education | 1 | 2018 | 104 | 0.140 |
Why?
| | Sulfides | 7 | 2014 | 95 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1514 | 0.140 |
Why?
| | Patient Selection | 1 | 2021 | 660 | 0.140 |
Why?
| | Benzyl Alcohols | 1 | 2016 | 2 | 0.130 |
Why?
| | Chlorobenzenes | 1 | 2016 | 9 | 0.130 |
Why?
| | Airway Remodeling | 1 | 2016 | 64 | 0.130 |
Why?
| | Child Care | 1 | 2016 | 26 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2511 | 0.130 |
Why?
| | Adult | 13 | 2023 | 35634 | 0.130 |
Why?
| | Eczema | 2 | 2014 | 67 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1708 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2271 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2019 | 2016 | 0.120 |
Why?
| | Bronchoconstrictor Agents | 2 | 2006 | 16 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2016 | 483 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 220 | 0.110 |
Why?
| | Lectins | 1 | 2014 | 48 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2016 | 766 | 0.110 |
Why?
| | Adipokines | 1 | 2014 | 47 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 304 | 0.110 |
Why?
| | Teaching | 1 | 2016 | 218 | 0.110 |
Why?
| | Obesity | 2 | 2017 | 2885 | 0.110 |
Why?
| | Prognosis | 2 | 2016 | 3773 | 0.110 |
Why?
| | Food Hypersensitivity | 1 | 2016 | 177 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 253 | 0.100 |
Why?
| | Overweight | 1 | 2017 | 531 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3089 | 0.100 |
Why?
| | Virus Diseases | 1 | 2015 | 210 | 0.100 |
Why?
| | Body Height | 2 | 2011 | 192 | 0.100 |
Why?
| | Age Factors | 3 | 2016 | 3161 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 592 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 763 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1005 | 0.090 |
Why?
| | Genomics | 1 | 2016 | 716 | 0.090 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2021 | 20 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2018 | 287 | 0.090 |
Why?
| | Recurrence | 3 | 2016 | 1013 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 376 | 0.090 |
Why?
| | Schools | 2 | 2018 | 443 | 0.090 |
Why?
| | Dexamethasone | 2 | 2005 | 352 | 0.090 |
Why?
| | Immunoglobulin E | 3 | 2015 | 330 | 0.090 |
Why?
| | Young Adult | 4 | 2022 | 12467 | 0.080 |
Why?
| | Symptom Flare Up | 2 | 2020 | 38 | 0.080 |
Why?
| | Vital Capacity | 3 | 2022 | 290 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2724 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1045 | 0.080 |
Why?
| | Skin Tests | 2 | 2015 | 100 | 0.080 |
Why?
| | Time Factors | 3 | 2008 | 6550 | 0.080 |
Why?
| | Drug Synergism | 2 | 2008 | 370 | 0.080 |
Why?
| | Growth | 2 | 2018 | 59 | 0.080 |
Why?
| | Caregivers | 1 | 2016 | 809 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 851 | 0.070 |
Why?
| | Immunotherapy | 1 | 2012 | 596 | 0.070 |
Why?
| | Hypersensitivity | 2 | 2018 | 249 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1284 | 0.070 |
Why?
| | Adenosine Monophosphate | 1 | 2007 | 63 | 0.070 |
Why?
| | Respiratory Tract Diseases | 1 | 2008 | 149 | 0.070 |
Why?
| | Drug Resistance | 2 | 2018 | 165 | 0.060 |
Why?
| | Inflammation | 4 | 2005 | 2748 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 234 | 0.060 |
Why?
| | Cohort Studies | 3 | 2011 | 5444 | 0.060 |
Why?
| | Drug Combinations | 2 | 2019 | 331 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 998 | 0.060 |
Why?
| | Weight Gain | 1 | 2009 | 510 | 0.060 |
Why?
| | Treatment Failure | 2 | 2020 | 339 | 0.060 |
Why?
| | Incidence | 2 | 2016 | 2646 | 0.060 |
Why?
| | Administration, Oral | 3 | 2013 | 787 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2008 | 1501 | 0.060 |
Why?
| | Bone Density | 1 | 2008 | 463 | 0.060 |
Why?
| | Biopsy | 2 | 2005 | 1089 | 0.060 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1110 | 0.050 |
Why?
| | Eosinophil Granule Proteins | 1 | 2003 | 21 | 0.050 |
Why?
| | Logistic Models | 2 | 2010 | 1989 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2015 | 5085 | 0.050 |
Why?
| | Global Health | 1 | 2006 | 329 | 0.050 |
Why?
| | Age of Onset | 3 | 2014 | 494 | 0.050 |
Why?
| | Age Distribution | 1 | 2004 | 372 | 0.050 |
Why?
| | Sex Distribution | 1 | 2004 | 359 | 0.050 |
Why?
| | Health Status | 1 | 2008 | 758 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 422 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2009 | 903 | 0.050 |
Why?
| | Clarithromycin | 1 | 2001 | 28 | 0.050 |
Why?
| | Research | 2 | 2022 | 420 | 0.050 |
Why?
| | Environmental Exposure | 1 | 2006 | 463 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 72 | 0.050 |
Why?
| | Bronchi | 1 | 2003 | 249 | 0.050 |
Why?
| | Fungi | 1 | 2023 | 136 | 0.050 |
Why?
| | Trachea | 1 | 2023 | 231 | 0.050 |
Why?
| | Blood Proteins | 1 | 2003 | 245 | 0.040 |
Why?
| | Cushing Syndrome | 1 | 2000 | 10 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2005 | 1434 | 0.040 |
Why?
| | Dyspnea | 1 | 2022 | 239 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 70 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 254 | 0.040 |
Why?
| | Geography | 1 | 2021 | 189 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 216 | 0.040 |
Why?
| | Moraxella | 1 | 2019 | 5 | 0.040 |
Why?
| | Carnobacteriaceae | 1 | 2019 | 3 | 0.040 |
Why?
| | Medication Adherence | 2 | 2019 | 561 | 0.040 |
Why?
| | Streptococcus | 1 | 2019 | 26 | 0.040 |
Why?
| | Staphylococcus | 1 | 2019 | 74 | 0.040 |
Why?
| | Exercise Test | 1 | 2022 | 614 | 0.040 |
Why?
| | Nasal Mucosa | 1 | 2019 | 107 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 385 | 0.040 |
Why?
| | Middle Aged | 6 | 2019 | 31177 | 0.040 |
Why?
| | Animals | 2 | 2022 | 35409 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 36 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2564 | 0.040 |
Why?
| | United States | 3 | 2021 | 13913 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 47 | 0.040 |
Why?
| | Vitamin D | 1 | 2020 | 380 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 77 | 0.030 |
Why?
| | Sex Factors | 2 | 2016 | 1973 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 814 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1937 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2016 | 29 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 36 | 0.030 |
Why?
| | Placebo Effect | 1 | 2016 | 55 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 106 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 39 | 0.030 |
Why?
| | Fever | 1 | 2016 | 298 | 0.030 |
Why?
| | Anaphylaxis | 1 | 2016 | 99 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 175 | 0.030 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2014 | 19 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 12 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 357 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 2013 | 26 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1201 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 302 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2014 | 216 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 980 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1033 | 0.020 |
Why?
| | Colorado | 2 | 2014 | 4410 | 0.020 |
Why?
| | Prednisolone | 1 | 2011 | 82 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1242 | 0.020 |
Why?
| | Pain | 1 | 2016 | 791 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1326 | 0.020 |
Why?
| | Curriculum | 1 | 2016 | 928 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2274 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2062 | 0.020 |
Why?
| | Poverty | 1 | 2012 | 499 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2008 | 10 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 57 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4896 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 284 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 947 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 269 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2014 | 14553 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 45 | 0.020 |
Why?
| | Birth Weight | 1 | 2009 | 505 | 0.020 |
Why?
| | Oscillometry | 1 | 2006 | 37 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 640 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 86 | 0.010 |
Why?
| | Respiratory Hypersensitivity | 1 | 2005 | 65 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 1951 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3630 | 0.010 |
Why?
| | Basement Membrane | 1 | 2003 | 32 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 796 | 0.010 |
Why?
| | Interleukins | 1 | 2005 | 241 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1092 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2008 | 395 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2005 | 356 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2003 | 160 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2003 | 219 | 0.010 |
Why?
| | Steroids | 1 | 2002 | 158 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1847 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1465 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2703 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5437 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1597 | 0.010 |
Why?
| | Aged | 2 | 2005 | 22107 | 0.010 |
Why?
|
|
Covar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|